ClinicalTrials.gg
Not yet recruitingNCT05382832BTX/SCS/TMigUpdated May 19, 2022

Botox Vs Spinal Cord Stimulation in the Treatment of Refractory Migraine Clinical Trial

An interventional study of SCS and SCS in Migraine, sponsored by Europainclinics z.ú.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by Europainclinics z.ú. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2022, 4 years 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The clinical trial is focused on the treatment of selected patients with a migraine after implantation of spinal cord stimulator (SCS) based on previous neurological examination. Patients will be randomized and divided into two groups. According to randomization patients will receive saline or botox into the epidural space. The efficacy of treatment will be compared and estimated in both groups during different SCS settings. Data will be collected in pre-set time frames.

Read the detailed description

This study consists of a double-blind randomized cross-over controlled trial (RCT). Enrolled centers are National Hospital For Neurology and Neurosurgery in London in the United Kingdom, EuroPainClinics® with centers in Bratislava, Košice, and Bardejov in the Slovac republic and also EuroPainClinics® with centers Praha, Brno, Ostrava, and Hradec Kralove in the Czech republic.

Patients with diagnosing migraine (examined previously by neurologist) suitable for participating in the clinical trial, without any previous Botulinum Toxin treatment or Spinal Cord Stimulation therapy, (after exact consultation by neuromodulation team) will be offered to enroll in the BoStiM trial.

Enrolled patients will have a full implant of Nevro Senza SCS system. The intervention will be performed at the National Hospital for Neurology and Neurosurgery in London in the United Kingdom, and also in st. Michal Hospital in Bratislava in the Slovak Republic and General University Hospital in Prague in the Czech Republic. The procedure will be performed by the Neuromodulation Team. The implanted SCS will be turned off at this stage and will stay off for 2 weeks' time to let the wounds heal properly and not interfere with headache measurements. Once enrolled in the study, the patients will be randomized into one of the two groups of study. Groups will consist in either first SCS treatment, then washout period, then Botox treatment or SCS, then washout, then Botox. All patients will therefore be their own controls, and all of them will receive both treatments. After randomization, patients will be added to the SCS pathway. During the period between enrolment and SCS implant, patients will have the opportunity to meet the psychology team at the Pain Management Centre (PMC) and will undergo teaching sessions to learn the basic SCS practical aspects.

Blinding technique:

In order to have a double-blinded RCT, the investigators will not be aware of the trial branch of the participants.

Injections will be performed either with Botulinum Toxin or with Normal Saline and Spinal Cord Stimulators will be configured in order to use high-frequency stimulation or a sham treatment. All Internal Pulse Generators (IPG) will be turned on throughout the trial so as to avoid the participants being able to know the treatment they're really receiving at that time. Participants receiving Botox injections will have their IPG running with a sham configuration. They will not be receiving any electric stimulation over the leads, but the battery will be programmed to have a current leakage and will need to be recharged so as if the IPG was properly working. This again is to avoid them knowing which treatment they're receiving at any time being. The Clinical Specialist Nurses (CNS) of our PMC will be in charge of labeling the Botox/Placebo vials, which will be anonymized, and they will also be in charge of setting up the SCS (sham or treatment).

Data collection:

The enrolled patients will be provided a Smartphone to assess the migraine episodes. Each Smartphone will have an in-built app that the patients will use daily, and that will send the results to the research team. Those patients preferring to use their own smartphone will need to download the app to their smartphone. The app will include a visual numeric scale (VNS) that the participants will need to fulfill daily, as well as qualitative questions including the type of migraine, the onset, presence or absence of aura, duration of the episode, and possible medication intake.

The first period of trial:

The proper trial period will start two weeks after the implant (week 1). On this day, patients will be invited to come to the PMC. Depending on the randomization group, patients will have either a Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode or a placebo injection and the IPG turned on in proper working mode. Patients will be given a controller for the IPG so that they may be able to turn it off in case of an emergency. They will nonetheless not be able to change the program. None of the investigators will be aware of the group. At week 12, participants will have a new injection of either Botox or Placebo and will be reviewed by the CNS and Nevro team to assess any problems. At that time, they will also be asked to complete through the Smartphone app the Quality of Life (QoL) questionnaires and will be asked to guess their branch. Washout period: At week 24, all participants will undergo a washout period of 1 month. They will be invited to come to the PMC and IPG (both sham and treatment) will be turned off. They will also be asked to fill the QoL questionnaires.

Second Period of Trial:

At week 28, participants will be invited to come to the PMC and they will start the second part of the trial, being assigned to the other branch. All IPG's will be turned on, those previously being actively treating will be turned to the sham mode and the opposite will be done with previously sham mode ones. Patients previously receiving placebo injections will receive a Botox injection on that day, and those previously receiving Botox injections will receive a placebo one. Quality of life questionnaires will be filled. At week 40, participants will undergo the 4th and last series of injections (Botox or placebo) and will have an assessment with CNS and Nevro team, and will be asked to fill in the usual questionnaires.

End of trial:

The trial will end at week 52 when patients will be asked to fill in the usual questionnaires. At that moment, they will be communicated to which branch they had been assigned.

Patients will then decide whether they want to keep the SCS system or prefer it removed.

02

Conditions studied

  • Migraine

Browse trials for

03

In context

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

This study's planned enrollment of 50 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

Europainclinics z.ú. is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • migraine presence

Exclusion criteria

Exclusion Criteria:

  • disagreement with participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    A1 Group SCS

    Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting two weeks after the SCS implant

    Combination Product: SCS

  • Experimental
    A1 Group Botox

    Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting two weeks after the SCS implant

    Combination Product: SCS

  • Placebo comparator
    B1 Group SCS

    Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting two weeks after the SCS implant

    Combination Product: SCS

  • Placebo comparator
    B1 Group Saline

    Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting two weeks after the SCS implant

    Combination Product: SCS

  • Experimental
    A2 Group SCS

    Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting at the 28th week of clinical trial investigation

    Combination Product: SCS

  • Experimental
    A2 Group Botox -after washout period

    Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting at the 28th week of clinical trial investigation

    Combination Product: SCS

  • Placebo comparator
    B2 Group SCS

    Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting at the 28th week of clinical trial investigation

    Combination Product: SCS

  • Placebo comparator
    B2 Group Saline -after washout period

    Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting at the 28th week of clinical trial investigation

    Combination Product: SCS

Interventions

06

What researchers measure

Primary outcomes

  1. Health Questionnaire (EQ-5D-5L)

    1 Graded from 1-5, where 1 means no problems in the area and 5 meaning extreme problems

    Time frame: 14 days after the SCS implant

  2. Health Questionnaire (EQ-5D-5L)

    Week 13 Graded from 1-5, where 1 means no problems in the area and 5 meaning extreme problems

    Time frame: 91 days after the SCS implant

  3. Health Questionnaire (EQ-5D-5L)

    Week 25 Graded from 1-5, where 1 means no problems in the area and 5 meaning extreme problems

    Time frame: 175 days after the SCS implant

  4. Health Questionnaire (EQ-5D-5L)

    Week 28 Graded from 1-5, where 1 means no problems in the area and 5 meaning extreme problems

    Time frame: 196 days after the SCS implant

  5. Health Questionnaire (EQ-5D-5L)

    Week 40 Graded from 1-5, where 1 means no problems in the area and 5 meaning extreme problems

    Time frame: 280 days after the SCS implant

  6. Health Questionnaire (EQ-5D-5L)

    Week 52

    Time frame: 364 dayss after the SCS implant

Secondary outcomes

  1. Visual numeric scale

    Time frame: daily up to 10 days

  2. Type of migraine

    Time frame: up to 1 week

  3. Aura presence

    Time frame: up to 1 week

  4. Duration of the migraine episode

    Time frame: up to 1 week

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2022; primary completion for Aug 2022, 0 months later.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 0 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 19, 2022
StartEst.
Aug 1, 2022
Primary completionEst.
Aug 1, 2022
CompletionEst.
Aug 1, 2025
Last update
May 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05382832
Lead sponsor
Europainclinics z.ú.
Collaborators
National Hospital for Neurology and Neurosurgery, London
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Aug 1, 2022 (estimated)
Primary completion
Aug 1, 2022 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
May 19, 2022

Study contacts

Ashish Shetty, MD, FRCA, FFPMRCA
Contact
drashshetty@gmail.com
+447723309217
Nicolas Varela, MD, DESA
Contact
+447723309217
Róbert Rapcan, MD, PhD, MBA, FIPP
study chair · EuroPainClincs
Ladislav Kočan, MD, PhD
study chair · EuroPainClincs

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Onabotulinum toxin A · Saline Solution

Start the discussion